This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Labopharm

BOSTON ( TheStreet) -- Pull up a six-month chart on Labopharm (DDSS) and you'd think something bad happened to the Canadian drug maker in early February. The stock went from around $1.40 last November all the way to a three-year high of just a penny under $3 on Feb. 3. But just as quickly, the stock round tripped under relentless selling pressure and is now back to around $1.60.

What happened in early February to trigger that much selling in Labopharm? Surprisingly, the U.S. Food and Drug Administration approved the company's new antidepressant Oleptro.

Yes, it was an FDA drug approval, not a rejection, which killed Labopharm's stock price. Confused? Many readers of the Biotech Stock Mailbag have been scratching their noggins over this one.

"I don't get it. Labopharm gets FDA approval and is about to launch a new drug into the multi-billion dollar anti-depression market but the stock is getting killed. Please explain what I'm missing here," writes Hank R.

Four Unique Stem Cell Therapies (Forbes)

Chris H. writes, "Could you do a piece on Labopharm? Do you think Labopharm is a buy at these levels? What kind of revenues do you see from their new depression drug?"

And "KIR465" pleads, "I bought Labopharm the day before the approval thinking it would go higher, but now I'm stuck. What should I do?"

Investors seem to be reacting to the approval of Oleptro as if the drug had been rejected because the commercial picture is very fuzzy. Oleptro is a once-daily formulation of trazadone, an anti-depressant and sleep aid that's been marketed since the early 1980s and is now generic and cheaply priced.

Oleptro is designed to be more convenient than the immediate-release form of trazadole currently prescribed by doctors, but is that enough to convince doctors to switch? And more importantly, will insurance companies reimburse patients who want to take Oleptro over a cheap generic?

The market has its doubts, which is why Labopharm's stock price plunged after Oleptro's approval. For its part, Labopharm has done little to assuage nervous investors. The company's approval was based on data comparing Oleptro to a placebo, which means there is little or no comparative data to demonstrate Oleptro's advantage over generic trazadone (other than convenience, which is a much tougher sell these days.)
1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
DNDN $0.06 -6.02%
CTIC $0.50 0.00%
CLDX $4.00 0.00%
NVS $75.97 0.00%
RNN $0.30 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs